Timothy Block Net Worth

Timothy Block biography

Dr. Timothy Block serves as Independent Director of the Company. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research). Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006, has led or “co-led” more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one of the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute’s Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of “outstanding achievements.” Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009, Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS). Dr. Block’s experience and expertise in the medical field with respect to Hepatitis B qualifies him to serve as a director of our Company.

What is the salary of Timothy Block?

As the Independent Director of Hepion Pharmaceuticals Inc, the total compensation of Timothy Block at Hepion Pharmaceuticals Inc is $96,111. There are 6 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.

How old is Timothy Block?

Timothy Block is 65, he's been the Independent Director of Hepion Pharmaceuticals Inc since 2013. There are 5 older and 6 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.

What's Timothy Block's mailing address?

Timothy's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.

Insiders trading at Hepion Pharmaceuticals Inc

Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard és John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.

What does Hepion Pharmaceuticals Inc do?

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.

Hepion Pharmaceuticals Inc executives and stock owners

Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Foster,
  Chief Executive Officer, Chief Scientific Officer, Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
  Pres, CEO & Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
  Pres, CEO & Director
• John T. Cavan,
  Chief Financial Officer
• John Cavan,
  Chief Financial Officer
• John Brancaccio,
  Independent Director
• Timothy Block,
  Independent Director
• Arnold Lippa,
  Independent Director
• Thomas Adams,
  Independent Director
• Gary Jacob,
  Chairman of the Board
• Stephen Kilmer,
  IR Contact Officer
• Peter Wijngaard,
  Independent Director
• Dr. Stephen A. Harrison,
  Member of Scientific Advisory Board & Consultant Medical Director
• Dr. John Z. Sullivan-Bolyai,
  Part-Time Consultant
• Dr. Todd M. Hobbs M.D.,
  Chief Medical Officer
• Dr. Patrick Mayo Ph.D.,
  Sr. VP of Clinical Pharmacology
• Dr. Daniel Trepanier Ph.D.,
  Sr. VP of Drug Devel.
• Sharen Pyatetskaya,
  Director of Investor Relations
• Dr. Daren Ure Ph.D.,
  Chief Scientific Officer
• Michael J. Purcell,
  Director
• Kaouthar Lbiati,
  Director